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Abstract: The pivotal cell involved in the pathogenesis of liver fibrosis, i.e., the activated hepatic
stellate cell (HSC), has a wide range of activities during the initiation, progression and even regression
of the disease. These HSC-related activities encompass cellular activation, matrix synthesis and
degradation, proliferation, contraction, chemotaxis and inflammatory signaling. When determining
the in vitro and in vivo effectivity of novel antifibrotic therapies, the readout is currently mainly based
on gene and protein levels of α-smooth muscle actin (α-SMA) and the fibrillar collagens (type I and
III). We advocate for a more comprehensive approach in addition to these markers when screening
potential antifibrotic drugs that interfere with HSCs. Therefore, we aimed to develop a gene panel for
human in vitro and ex vivo drug screening models, addressing each of the HSC-activities with at
least one gene, comprising, in total, 16 genes. We determined the gene expression in various human
stellate cells, ranging from primary cells to cell lines with an HSC-origin, and human liver slices
and stimulated them with two key profibrotic factors, i.e., transforming growth factor β (TGFβ) or
platelet-derived growth factor BB (PDGF-BB). We demonstrated that freshly isolated HSCs showed
the strongest and highest variety of responses to these profibrotic stimuli, in particular following
PDGF-BB stimulation, while cell lines were limited in their responses. Moreover, we verified these
gene expression profiles in human precision-cut liver slices and showed similarities with the TGFβ-
and PDGF-BB-related fibrotic responses, as observed in the primary HSCs. With this study, we
encourage researchers to get off the beaten track when testing antifibrotic compounds by including
more HSC-related markers in their future work. This way, potential compounds will be screened
more extensively, which might increase the likelihood of developing effective antifibrotic drugs.
Keywords: drug development; primary hepatic stellate cells; precision-cut liver slices; myofibroblast;
reversion; fibrosis gene panel; transforming growth factor β; platelet-derived growth factor BB
1. Introduction
In liver fibrosis research, when screening the efficacy of a promising new antifibrotic compound,
the current gold standards to assess the in vivo antifibrotic efficacy are α-smooth muscle actin (α-SMA)
and collagens type I and III. α-SMA is highly expressed by the pathogenic-activated hepatic stellate
cells (HSCs) that transform into myofibroblasts in the fibrotic liver [1]. In addition, the deposited
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interstitial collagen fibrils are predominantly produced by these cells [1]. Collagenases such as matrix
metalloproteinases (MMPs) and certain profibrotic cytokines like transforming growth factor β (TGFβ)
are sometimes added as markers for HSC activities [2]. However, the involvement of HSCs in fibrosis
is very diverse, and thus only taking into account these few markers might leave other relevant
characteristics of the HSCs underexposed.
Upon liver injury, HSCs are activated to develop into myofibroblasts following a response
that is associated with the release of a variety of profibrogenic mediators, of which TGFβ and
platelet-derived growth factor BB (PDGF-BB) are established as the central players [3]. Although
other hepatic cells including portal fibroblasts, bone marrow-derived mesenchymal cells (fibrocytes)
and epithelial/endothelial cells transition into mesenchymal cells (EMT/EndMT), and can contribute
to the myofibroblast pool as well, their contribution in cell numbers is much lower [4–7]. It was
recently assessed that 82–96% of the myofibroblast pool in models of toxic-, cholestatic- and fatty-liver
disease originates from hepatic stellate cells [8]. Following the initiation of HSC activation and
transdifferentiation into myofibroblasts, perpetuation of the response occurs, indicating an amplification
and expansion of the activated state. This is associated with phenotypic changes, altered matrix synthesis
and degradation, increased proliferation, chemotaxis and contraction [3,9]. As a consequence, during
this transition, HSCs typically lose their cytoplasmic lipid droplets, which mainly contain vitamin
A compounds. When the hepatic injury and the subsequent inflammatory response persist, the
fibrogenesis and matrix deposition becomes problematic and may progress from fibrosis to irreversible
stages of cirrhosis [3].
It is nowadays commonly accepted that fibrosis, even in advanced stages, is reversible upon
eradication of the inciting stimulus or can be induced by (antifibrotic) drugs [10]. The exact mechanisms
of reversion are not elucidated yet, but a crucial event involves the regression of activated HSCs and
myofibroblasts [9]. This might occur via apoptosis, cellular senescence, clearance by immune cells or
reversion to a less activated cell state [11]. These reverted or inactivated HSCs share various similarities
with quiescent HSC. However, they also express different genes and are more primed to fibrogenic
stimuli, such as TGFβ, as compared to quiescent cells [10,12,13].
Currently, patients suffering from end-stage liver disease can only be cured by organ
transplantation, of which the availability is limited [14]. Therefore, effective antifibrotic drugs
are urgently needed but the success of the clinical trials is low and needs long-term evaluations.
To improve and accelerate drug development, reliable and comprehensive in vitro screening methods
to test putative compounds are indispensable. Moreover, these screening methods should primarily
focus on human models [14]. The preclinical outcomes in animal models do not always correlate
well with the human situation due to species differences, and this is one of the causes of unnecessary
preclinical rejection of potential compounds [15].
Since the activated HSCs are an important target for future drug intervention of hepatic fibrosis,
in our current study we focused on this pivotal cell type with in vitro studies in primary human cells
and commonly used human HSC lines, and with ex vivo studies using precision-cut liver slices (PCLS).
PCLS, freshly prepared from residual human livers, represent an ex vivo tissue culture technique that
retains the multicellular characteristics of the hepatic (fibrotic) environment in vivo [15]. In our studies,
we assessed the HSC activities in response to the two key profibrotic factors, TGFβ and PDGF-BB.
While TGFβ is predominantly known for its role in cellular activation and transformation, and in matrix
biology, PDGF-BB is more involved in the survival, proliferation and chemotaxis of HSCs [16]. In the
used in vitro and ex vivo human models, we looked beyond α-SMA and collagens, typically regulated
by TGFβ, and we now present a panel of genes related to the versatile HSC activities in fibrogenesis
and fibrolysis, thereby providing a framework that could improve antifibrotic drug development.
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2. Materials and Methods
2.1. Cell Cultures
Human livers were obtained under the University College London—Royal Free BioBank Ethical
Review Committee, reference number: NC2015.020 (B-ERC-RF) after informed consent was obtained for
each donor. Primary human hepatic stellate cells (pHSC) were freshly isolated from these human livers
as described before [17] and cultured in Iscove’s Modified Dulbecco’s Medium, supplemented with
20% fetal bovine serum (FBS) performance plus, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM
l-glutamine, 1 mM sodium pyruvate, 1×Minimal Essential Medium (MEM) non-essential amino acids
solution and 250 ng/mL amphotericin B. The Human Hepatic Stellate Cells (HHSteC) were obtained from
ScienCell Research Laboratories (Carlsbad, CA, USA), and cultured in poly-l-lysine (Sigma-Aldrich,
St. Louis, MO, USA)-coated flasks and plates in complete stellate cell medium containing 2% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin and 1% stellate cell growth supplement (all ScienCell
Research Laboratories). HHSteCs and pHSCs were sub-cultured up to 5 times, ensuring minimal
variation in the myofibroblast activation state. LX-2 hepatic stellate cells were kindly provided by
prof. Scott Friedman (Mount Sinai Hospital, New York, NY, USA) [18]. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, GlutaMAX™) containing 10% FBS, supplemented with
100 U/mL penicillin and 100 µg/mL streptomycin. TWNT-4 hepatic stellate cells were cultured in
DMEM containing 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM·L-glutamine [19].
Cells were plated in 12-well plates (for pHSC 70,000 cells/well, for HHSteC 125,000 cells/well, and
for LX-2 and TWNT-4 50,000 cells/well) and either not stimulated (control), or stimulated for 24 h with
5 ng/mL TGFβ1 or 50 ng/mL PDGF-BB (both PeproTech, London, Great Britain), and harvested for
RNA isolation and cDNA synthesis. Materials were purchased at Thermo Fisher Scientific (Waltham,
MA, USA) unless stated otherwise. Photomicrographs of the different cell types were captured at 40×
and 100×magnification.
2.2. Precision-Cut Liver Slices (PCLS)
Healthy human liver tissue was obtained from donor organs unsuitable for transplantation,
resized donor organs and unaffected tissue of patients undergoing surgical excision of carcinoma.
The experimental protocols were approved by the Medical Ethical Committee of the University Medical
Center Groningen. Precision-cut liver slices were prepared according to standard procedures, as
described previously [15,20]. In short, livers (n = 4) were sliced in enhanced ice-cold carbogen-saturated
Krebs–Henseleit buffer and cut with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) at
250–300 µm thickness and 4–5 mg wet weight. Slices were stored in University of Wisconsin (UW) until
incubation for 48 h in 12-well plates filled with 1.3 mL William’s E Medium (Thermo Fisher Scientific)
enriched with 25 mM glucose (Merck, Kenilworth, NJ, US) and 50 µg/mL gentamycin (Thermo Fisher
Scientific), either not supplemented (control) or supplemented with 5 ng/mL TGFβ1 or 50 ng/mL
PDGF-BB (both PeproTech). Culture medium was refreshed every 24 h. Wells of slices incubated with
TGFβ1 were precoated with 10% bovine serum albumin (BSA) solution (Sigma-Aldrich). Per condition,
3 slices were pooled and snap-frozen for RNA isolation and cDNA synthesis.
2.3. Quantitative Real-Time Polymerase Chain Reaction (PCR)
Total RNA was isolated from cells or precision-cut liver slices using a Maxwell® LEV simply RNA
Cells/Tissue kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions. RNA
concentrations were determined using a NanoDrop One spectrophotometer (Thermo Fisher Scientific).
Conversion of RNA to cDNA was performed using MLV (murine leukemia virus) reverse transcriptase
(Promega) in an Eppendorf Mastercyler gradient device, with the gradient at 20 ◦C for 10 min, 42 ◦C for
30 min, 20 ◦C for 12 min, 99 ◦C for 5 min and 20 ◦C for 5 min. The transcription levels were measured
in 10 ng cDNA by quantitative real-time PCR (SensiMix™ SYBR® Low-ROX Kit, Bioline, Taunton,
MA, USA) using a QuantStudio 7 Flex Real-Time PCR system (hold stage: 95 ◦C for 10 min; PCR
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stage: 40 cycles of 95 ◦C for 15 s and 60 ◦C for 25 s; melt curve stage: 95 ◦C for 15 s, 60 ◦C for 1 min
and 95 ◦C for 15 s). Data was analyzed using QuantStudio Real-Time PCR software (Thermo Fisher
Scientific). For each model, mRNA expression was normalized to housekeeping genes (either ACTB
for primary HSC and LX-2, or RNA18S5 for HHSteC, TWNT-4 and PCLS), and expressed as 2−∆∆Ct
(fold induction). Differences between treatment groups and untreated controls are in the main text
referred to as percentage increase or decrease. The used primer sequences are listed in Table 1.
Table 1. Primer sequences used for quantitative real-time PCR.
Gene Symbol Full Gene Name Sequence Forward Sequence Reverse
ACTA2 Alpha smooth muscle actin CCCCATCTATGAGGGCTATG CAGTGGCCATCTCATTTTCA
PDGFRB Platelet-derived growth factorreceptor beta GTAAGGTGCCAACCTGCAAT CATGGGGGTATGGTTTTGTC
CCN2 Cellular communicationnetwork factor 2 GACTGGAAGACACGTTTGGC CTTCCAGGTCAGCTTCGCAA
COL1A1 Collagen type I alpha 1 chain GTACTGGATTGACCCCAACC CGCCATACTCGAACTGGAAT
FN1 Fibronectin 1 AGGCTTGAACCAACCTACGGATGA GCCTAAGCACTGGCACAACAGTTT
TIMP1 Tissue inhibitor ofmetalloproteinases 1 AATTCCGACCTCGTCATCAG TGCAGTTTTCCAGCAATGAG
CCND1 Cyclin D1 GACCCCGCACGATTTCATTG AAGTTGTTGGGGCTCCTCAG
MKI67 Marker of proliferation Ki-67 CGTCCCAGTGGAAGAGTTGT CCCCTTCCAAACAAGCAGGT
MYLK Myosin light-chain kinase GGTGACATGGCACAGAAACG AGCTGCTTCGCAAAACTTCC
ROCK2 Rho-associated coiledcoil-containing protein kinase 2 AACGTCAGGATGCAGATGGG CAGCCAAAGAGTCCCGTTCA
CCL2 C-C motif chemokine ligand 2 CTCGCTCAGCCAGATGCAAT TCCATGGAATCCTGAACCCAC
CCL5 C-C motif chemokine ligand 5 TGCTGCTTTGCCTACATTGC CACACTTGGCGGTTCTTTCG
TNF Tumor necrosis factor alpha CGTCTCCTACCAGACCAAGG CCAAAGTAGACCTGCCCAGA
CXCL8 C-X-C motif chemokine ligand 8 TGCAGTTTTGCCAAGGAGTG CAACCCTCTGCACCCAGTTT
PPARG Peroxisome proliferatoractivated receptor gamma AGGAAGGGGCCTTAACCTCT CACGGAGCTGATCCCAAAGT
CYGB Cytoglobin GTCATTCTGGAGGTGGTCGC GTGGAGTTAGGGGTCCTACG
ACTB Beta actin CCTCGCCTTTGCCGATCC AGGAATCCTTCTGACCCATGC
RNA18S5 RNA, 18S ribosomal N5 CGGCTACCCACATCCAAGGA CCAATTACAGGGCCTCGAAA
2.4. Statistical Analyses
At least 3 individual experiments were done, and these data are represented as mean ± standard
error of the mean (SEM). The graphs and statistical analyses were performed in GraphPad Prism
version 8.0 (GraphPad Software, San Diego, CA, USA). Statistical differences were assessed on 2−∆∆Ct
values by the Kruskal–Wallis test followed by Dunn’s multiple comparison test.
3. Results
3.1. Morphology of the in Vitro Models
We evaluated the gene panel in human HSCs with diverse backgrounds. In addition to primary
HSCs, both freshly isolated from human livers (primary HSC) and obtained from a commercial source
(HHSteC), we also include the immortalized HSC-lines LX-2 and TWNT-4 in our studies. First, these
HSCs were examined for their morphology. All cultures displayed more or less the characteristic
stellate star shape (Figure 1). The freshly isolated primary HSCs were bigger and had more elongated
cell bodies compared to the other cell types. Upon culturing, all cells proliferated and became fully
activated, which is characterized by their myofibroblast-like stretched polygon morphologies, and as a
result, they lost their lipid droplet content.
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Figure 1. Morphology of various human stellate cell cultures (primary hepatic stellate cell (HSC),
HHSteC, LX-2 and TWNT-4 cells). Representative light microscopy images were captured at 40× and
100×magnification at 1 day after seeding.
3.2. Fβ- and PDGF- B-Related Fibrotic Responses in Primary Human Hepatic Stellate Cells
All HSCs were stimulated with either TGFβ or PDGF-BB, after which we assessed the expression
of a panel of HSC-associated genes during fibrosis. The results classified according to the type of
activity are shown in Figure 2. In the primary HSCs, several activation and fibrogenesis genes were
significantly increased following stimulation with TGFβ (ACTA2 71.8% ± 12.8%, CCN2 125.2% ± 12.8%,
COL1A1 46.4% ± 7.7%, FN1 49.2% ± 15.5%), as well as in HHSteCs (ACTA2 410.8% ± 78.9%, CCN2
702.5% ± 299.4%, COL1A1 170.5% ± 65.2%, FN1 264.4% ± 81.7%) (Figure 2A,B). In the HHSteCs,
the expression of TIMP1 was also significantly increased (30.6% ± 8.5%) (Figure 2C). Interestingly,
expression of the contractility markers MYLK (62.7% ± 2.6%) and ROCK2 (34.2% ± 3.9%) in primary
HSCs (Figure 2E) was markedly reduced. Similarly, the reversion was assessed with the HSC quiescent
markers CYGB and PPARG. The expression of CYGB (39.5% ± 2.4% and 77.6% ± 7.2% in primary HSCs
and HHSteCs, respectively) and PPARG (68.1% ± 12.9% in HHSteCs) was significantly lower compared
to cells not sti ulated ith TGFβ (Figure 2H), indicating the activation of the HSCs.
Upon stimulation with PDGF-BB, proliferation genes were markedly increased in both the primary
HSCs (CCND1 8.6 1 .1 , MKI67 151.2%± 49.8%) and he HHSte s (CCND1 105.9%± 32.7%, MKI67
79.4% ± 25. %) (Figure 2D). The infl mmatory gene CXCL8 was increased as well (598.9% ± 247.0% in
primary HSCs and 1743.4% ± 684.1% in HHSteCs, respectively) (Figure 2G). Moreover, TIMP1 and
CCL2 xpression were clearly induced by PDGF-BB in the prim ry HSC cultures (40.6% ± 12.6% and
79.8% ± 20.7%) (Figure 2C,F). Remarkably, several activation genes that were increased after TGFβ
stimulation were significantly expressed lower in primary HSCs (ACTA2 64.9%± 3.85%, PDGFRB 45.8%
± 2.7%, CCN2 26.8% ± 4.8%) and in HHSteCs (PDGFRB 43.9% ± 9.31%) after incubation with PDGF-BB
(Figure 2A). More genes were responsive in primary HSCs as compared to HHSteCs, particularly
following PDGF-BB stimulation, showing the added value of these primary cells.
Both primary HSC types showed stronger responses to either TGFβ- or PDGF-BB-stimulation as
compared to the HSC-lines LX-2 and TWNT-4. LX-2 cells did show a clear increase in activation and
fibrogenesis genes upon TGFβ-stimulation (ACTA2 62.4% ± 12.3%, PDGFRB 86.0% ± 10.7%, CCN2
150.6% ± 18.0%, COL1A1 165.3% ± 6.2%, FN1 139.2% ± 15.1%), whereas the gene expression of COL1A1
was increased in TWNT-4 cells (91.3% ± 28.7%) (Supplementary Figure S1A,B). Of note, both cell lines
showed hardly any effect on gene expression after PDGF-BB stimulation (Supplementary Figure S1),
and therefore the suitability of these cell lines for fibrosis research should be carefully considered.
We summarized the differences in gene expressions of all cells in a heatmap, in which increased
expressions as compared to control are depicted in red, and reduced expressions are shown in green
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Figure 2. In vitro effects of TGFβ or PDGF-BB on the gene expression of markers for HSC-activities
during fibrosis in primary HSCs (n = 11, 3 different donors) and HHSteCs (n = 4). HSC-activities and
their associated genes include (A) activation (ACTA2, PDGFRB, CCN2), (B) fibrogenesis (COL1A1, FN1),
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(C) altered matrix degradation (TIMP1), (D) proliferation (CCND1, MKI67), (E) contractility (MYLK,
ROCK2), (F) chemotaxis (CCL2, CCL5), (G) inflammatory signaling (CXCL8) and (H) reversion (PPARG,
CYGB). The Ct values of CCL5 and PPARG in primary HSCs and TNF in both cell types were not
detectable. Fold inductions are relative to untreated controls.
Table 2. Heatmap visualizing the fold inductions of all cells studied and stimulated with TGFβ and
PDGF-BB relative to the untreated control. Rows represent genes related to the versatile HSC activities
in fibrogenesis and fibrolysis. Columns represent the tested cell types. Red color indicates increased
gene expression (dark red p < 0.05; light red 0.05 ≤ p < 0.10) and green indicates reduced expression
(dark green p < 0.05; light green 0.05 ≤ p < 0.10) as compared to control. No significant effect or no gene























3.3. TGFβ- and PDGF-BB-Related Fibrotic Responses in Human Precision-Cut Liver Slices
To determine the gene expression levels of the different markers in a more comprehensive in vitro
model, in which the in vivo liver environment is resembled, we also stimulated human precision-cut
liver slices with either TGFβ or PDGF-BB. Although the change in expression was less pronounced as
compared to the cell cultures, similar trends were found in the gene expressions (Figure 3). Stimulation
of PCLS with TGFβ markedly increased the expression of TIMP1 (137.4% ± 60.8%) and showed a
clear increasing trend in expression of activation and fibrogenesis markers (ACTA2 189.6% ± 152.2%,
PDGFRB 52.7% ± 53.2% and COL1A1 93.6% ± 69.9%) (Figure 3A–C). Interestingly, the expression of
PPARG seemed to be reduced (23.1% ± 14.9%), which was again comparable to the in vitro results
(Figure 3H).
Well in line with the in vitro results, PDGF-BB stimulation clearly increased the expression of
proliferation markers CCND1 and MKI67 (86.4%± 37.7% and 165.0%± 47.3%), TIMP1 (335.6%± 118.0%)
and COL1A1 (180.6% ± 73.4%) (Figure 3B–D). Additionally, the chemotactic gene CCL2 is expressed
higher compared to the untreated control (99.9% ± 49.7%) (Figure 3F).
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with  one  of  the  two main  profibrotic mediators,  i.e.,  transforming  growth  factor  β  (TGFβ)  and 
Figure 3. Gene expression levels of several markers for HSC-activities during fibrosis in human
precision-cut liver slices (n = 4) stimulated with TGFβ or PDGF-BB. HSC activities and their associated
genes include (A) activation (ACTA2, PDGFRB, CCN2), (B) fibrogenesis (COL1A1, FN1), (C) altered
matrix degradation (TIMP1), (D) proliferation (CCND1, MKI67), (E) contractility (MYLK, ROCK2), (F)
chemotaxis (CCL2, CCL5), (G) inflammatory signaling (TNF, CXCL8) and (H) reversion (PPARG, CYGB).
Fold inductions are relative to untreated controls.
4. Discussion
The increasing incidence of patients with liver cirrhosis, combined with the lack of effective
antifibrotic drugs to stop or reverse the disease, urgently demands drug development [14,21]. Clearly,
activated HSCs have an important and versatile role in the development and progression of fibrosis
of various etiologies, and are therefore an interesting therapeutic target [3,22]. Nowadays, several
clinical trials focus on the HSC and study the effects of drugs that directly interfere with this cell
type. Examples include the PPARy-agonist pioglitazone, and the dual CCR2/CCR5 receptor-antagonist
cenicriviroc [3]. Despite the efforts, there is no curative treatment option for hepatic fibrosis on the
market yet. When it comes to antifibrotic drug discovery and development, only evaluating the effect
on α-smooth muscle actin (α-SMA) and collagens may give limited information. In fact, in our view, it
is preferred to test promising antifibrotic compounds by a more extensive screening in human models
with a variety of read-out parameters in order to boost drug discovery. We therefore developed a human
gene panel that includes most of the previously defined HSC-activities during fibrosis. The panel
accommodates, in total, 16 fibrotic HSC-related genes, which we tested on several human HSC-cell
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lines and primary cells, and on human precision-cut liver slices (PCLS) stimulated with one of the two
main profibrotic mediators, i.e., transforming growth factor β (TGFβ) and platelet-derived growth
factor BB (PDGF-BB). In the present study, we showed that freshly isolated HSCs have the strongest
and most versatile response towards both profibrotic cytokines and is the most suitable system to test
antifibrotic responses in future studies. In addition, liver slices, resembling the patient situation even
better, showed analogous responses.
Following the activation of HSCs, the perpetuation phase is induced as the injury persists,
which involves the proliferation, contraction, fibrogenesis, altered matrix degradation, chemotaxis
and inflammatory signaling of the activated phenotype [3]. All these different aspects are typically
regulated by either TGFβ or PDGF-BB and this can also be seen in the used primary HSCs (Figure 2)
and slice model system (Figure 3). A multitude of other fibrogenic substances, such as connective
tissue growth factor (CTGF), osteopontin (OPN), reactive oxygen species (ROS), tumor necrosis factor
α (TNFα) and interleukin 1 β (IL-1β), contribute to the activation and proliferation of HSCs, but these
are not as potent as TGFβ and PDGF-BB [23]. TGFβ characteristically promotes cellular activation
(α-SMA) and increases extracellular matrix (ECM) deposition (including collagen type I and III and
fibronectin), which is induced via intracellular Smad2/3 signaling [24]. TGFβ is also involved in the
inhibition of matrix degradation, via suppression of matrix metalloproteinases (MMP1, 8, 13) and
induction of tissue inhibitors of metalloproteinases (TIMP1, 2) and plasminogen activator inhibitor
(PAI) [25]. PDGF-BB is the most potent growth factor essential in survival, proliferation and chemotaxis
of HSCs via activation of Protein kinase B (PKB), also known as Akt, and extracellular signal-regulated
kinase (ERK) 1/2 signaling [26]. In our studies, we clearly showed PDGF-induced expression of
CCND1, MKI67 and CCL2 in primary HSCs and HHSteCs. Of note, in the HSC-lines that we studied as
well (Supplementary Figure S1), we could not detect changes in gene expression profiles after PDGF
stimulation, in contrast to their preserved TGFβ responsiveness. This may show the limitations of
these cell lines. Furthermore, PCLS responded well to PDGF with significantly increased expression of
the corresponding parameters (Figure 3D–F) delineating the suitability of this ex vivo test system.
Removal of the fibrotic stimulus or treatment with an effective antifibrotic therapy would result in
amelioration of hepatic fibrosis, associated with the resolution of the inflammatory response and the
reduction and reversion of activated HSCs [27,28]. Studies in mice indicated that during resolution
of liver fibrosis, approximately 50% of the activated HSCs escape from apoptosis and acquire an
inactivated phenotype that is similar but not completely identical to quiescent HSCs [13]. These
inactivated HSCs are in a primed state for reactivation in response to additional fibrogenic injury,
and reacquire some, but not all characteristics of quiescent HSCs present in the healthy liver [12,13].
Here, we proposed PPARG and CYGB as markers for the quiescence of HSCs [29,30], and showed in
the primary HSCs that these gene expressions are reduced predominantly by TGFβ stimulation, i.e.,
upon TGFβ-induced HSC activation. It is to be expected that the expression levels of these genes are
increased when drugs with antifibrotic potential are tested, indicating the reversion of the disease.
As previously mentioned, there is no effective therapy for fibrosis available on the market yet,
despite several compounds that were shown to effectively reduce fibrotic parameters both in vitro and
in animal models [31]. An important problem when in vitro and in vivo data from animal experiments
are translated to the human situation is the interspecies differences [20]. Depending on the studied
species, the fibrotic process including interactions between cells, cytokines, extracellular matrix proteins,
as well as the intracellular signaling, can be different. Therefore, it is of major importance to test
potential antifibrotic compounds in validated human systems.
Using monocultures of hepatic stellate cells of human origin, the role of the key pathogenic cell
type involved in liver fibrogenesis and the effectivity of drugs can be studied in detail. In addition, this
can be studied in PCLS as well, in which the HSCs are present in their original microenvironment [15].
We observed similar fibrotic responses in the PCLS as detected in the primary HSCs, albeit less
pronounced. This is mainly attributed to the presence of several different cell types, all contributing to
the total gene expression. Of note, other hepatic cell populations including hepatocytes, Kupffer cells
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and cholangiocytes might also respond to the profibrotic stimuli TGFβ and PDGF-BB, thereby biasing
gene expression results. In particular, in PCLS, it is essential to select markers that are as exclusively
expressed by the HSC-population as possible. Obviously, in combination with the naturally occurring
variation in gene expression in human donor tissues, this means that higher repetition of experiments
is necessary in order to obtain statistically significant differences. A major advantage of PCLS is that
cell–cell interactions, for instance between HSCs and liver-resident macrophages (Kupffer cells), can be
included in the studies as well.
In this study, we used genetic markers to screen for the distinct functions of HSCs in hepatic
fibrosis, as selected from the large database of fibrosis markers available in literature. Evidently, the
choice for the markers per HSC function is open for interpretation and should be adapted at one’s own
discretion, depending on the mechanism of action of the potential antifibrotic compound. We intended
to create a framework for preclinical antifibrotic drug testing at the gene level. In addition to the
genetic markers, the complementary protein levels are interesting as well. Currently, a wide variety
of markers to be used in future clinical trials is under investigation. Methods include, for example,
immunohistochemical staining for collagens, α-SMA or PDGFβ-receptor to study liver histology,
elastography to determine liver stiffness and serum fibrosis markers [14].
In conclusion, model test systems to screen the antifibrotic potential of novel therapeutics should
include all aspects of HSC activities in fibrosis, and thus look beyond the standard markers such as
α-SMA and fibrillary collagens. The used models should be human-based, like primary HSCs or
precision-cut liver slices freshly isolated or prepared from human livers, as these models will better
predict therapeutic effects in patients. This way, the outcomes of in vitro studies with antifibrotic
compounds can be broadened, thereby boosting drug development in the fibrosis field.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/3/278/s1,
Figure S1: In vitro effects of TGFβ or PDGF-BB on the gene expression of markers for HSC-activities during
fibrosis in LX-2 and TWNT-4 cells (both n = 4), Table S1: Ct values ± SEM per gene of the untreated controls in all
used in vitro models as determined with quantitative real-time PCR.
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